Oncolytics Biotech (TSE:ONC) Stock Passes Above 200 Day Moving Average – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC)’s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$14.90 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares.

Oncolytics Biotech Stock Performance

The company has a debt-to-equity ratio of 14.58, a quick ratio of 8.86 and a current ratio of 2.88. The company has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The firm has a 50 day moving average price of C$14.90 and a 200-day moving average price of C$14.90.

Insider Activity

In related news, insider Jared Ryan Kelly acquired 29,500 shares of the business’s stock in a transaction on Thursday, February 12th. The stock was bought at an average cost of C$1.16 per share, with a total value of C$34,220.00. Following the completion of the acquisition, the insider owned 109,000 shares in the company, valued at C$126,440. The trade was a 37.11% increase in their ownership of the stock. Also, Director Patricia Andrews bought 35,400 shares of Oncolytics Biotech stock in a transaction dated Thursday, February 12th. The stock was purchased at an average price of C$1.18 per share, for a total transaction of C$41,772.00. Following the purchase, the director directly owned 78,128 shares in the company, valued at C$92,191.04. This represents a 82.85% increase in their position. Over the last ninety days, insiders acquired 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by company insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.